Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...

Bluebird bio Inc ( (BLUE) ) has released its Q3 earnings. Here is a breakdown of the information Bluebird bio Inc presented to its investors.

SOMERVILLE, Mass., November 14, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

Bluebird Bio (BLUE) Company Description: bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

Inc. ("bluebird bio" or the "Company") today announced that it partially adjourned its annual meeting of stockholders ("Annual Meeting") on Wednesday, November 6, 2024, to allow the Company to solicit ...

About bluebird bio, Inc. bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. Founded in 2010, bluebird has been setting the standard for gene ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...